The FDA’s decision to lift the clinical hold on Intellia Therapeutics (NTLA) MAGNITUDE Phase 3 trial and the new hereditary angioedema data for lonvoguran ziclumeran have refocused attention on the company’s gene editing pipeline.

At a share price of $13.44, Intellia has seen a 39.85% 90 day share price return and a 45.93% year to date share price return. The 5 year total shareholder return of 79.49% and 3 year total shareholder return of 62.48% underline how recent FDA decisions and new HAE data mark a shift after a long period of weaker performance.

If gene editing progress at Intellia has caught your attention, this could be a good moment to broaden your watchlist with 32 healthcare AI stocks that our screener has surfaced as potential ideas to research next.

So with Intellia trading at US$13.44, and with wide gaps to analyst targets alongside heavy losses and fresh clinical momentum, are you looking at an underappreciated CRISPR player or a stock where the market already prices in future growth?

Most Popular Narrative: 43.7% Undervalued

With Intellia at $13.44 against a narrative fair value of $23.86, the most followed view sees a wide gap that hinges on ambitious long term growth and margin assumptions.

The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends, especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE, supporting higher future patient volumes and underpinning potential multi launch revenue inflection points.

Curious what kind of revenue ramp, cash runway and future earnings power that narrative is baking in, and how rich the assumed future multiple really is?

Result: Fair Value of $23.86 (UNDERVALUED)

However, this depends on clean data and smooth execution, and any safety setback in nex-z or slower uptake compared with competing ATTR and HAE therapies could quickly challenge that optimism.

Next Steps

If this mix of optimism and caution feels familiar, now is a good time to look at the numbers yourself and decide where you stand. You can start with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Intellia has sharpened your focus, do not stop here. Give yourself options by lining up a few more ideas that fit different roles in your portfolio.

• Target potential value opportunities by reviewing 50 high quality undervalued stocks that our filters surface as candidates for further research.
• Strengthen your focus on financial resilience by scanning solid balance sheet and fundamentals stocks screener (41 results) that pair cleaner balance sheets with consistent fundamentals.
• Get ahead of the crowd by hunting through our screener containing 24 high quality undiscovered gems before other investors start paying close attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.